GE Healthcare

Catalent launches Quality, Product Development & Regulatory Affairs organization

Thursday, March 19, 2015 02:55 PM

Catalent Pharma Solutions, a Somerset, N.J.-based global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, has formed the Quality, Product Development & Regulatory Affairs organization, established to build upon Catalent’s experience in new product development, regulatory excellence, reliable supply and quality. Sharon Johnson, senior vice president, global quality & regulatory affairs, will head up Catalent’s new organization.

More... »

Quest Diagnostics

Life Sciences Hub Wales launched

Thursday, July 17, 2014 12:45 PM

The Welsh government has launched the Life Sciences Hub Wales, a national and international focal point for the life sciences and healthcare sectors in Wales. The life sciences hub will be based in Cardiff Bay and will bring together academic, business, clinical, professional services and funding organizations.

More... »


ERT partners with GE Healthcare

Friday, April 11, 2014 12:04 PM

ERT, a global solution provider for high-quality patient safety and efficacy endpoint data collection, has entered into an agreement with GE Healthcare that enables ERT to introduce the QT Guard Plus Analysis System to the clinical trial industry as part of its centralized cardiac safety solutions. 

More... »

CEOi, NY Academy of Sciences to launch Global Alzheimer's Platform

Wednesday, February 26, 2014 01:21 PM

The Global CEO Initiative (CEOi) on Alzheimer's Disease and the New York Academy of Sciences have convened representatives from industry, academia, government and nonprofits to launch the development of a Global Alzheimer's Platform (GAP), designed to reduce the time and costs of Alzheimer's clinical trials, develop an infrastructure that promotes innovation and assure international collaboration.

More... »

Report: U.S. Alzheimer's imaging agent market will grow as reimbursement improves

Thursday, February 13, 2014 03:03 PM

The U.S. Alzheimer's imaging agent market will grow dramatically over the next 10 years, according to Decision Resources Group. Currently, Eli Lilly's Amyvid, launched in June 2013, is the only FDA-approved product available, but GE Healthcare, Piramal Enterprises and Navidea Biopharmaceuticalsare all poised to launch products in the U.S. in the next few years.

More... »

GE acquires assets from Thermo Fisher Scientific

Monday, January 6, 2014 03:06 PM

GE Healthcare will acquire Waltham, Mass.-based Thermo Fisher Scientific’s HyClone cell culture (sera and media), gene modulation and magnetic beads businesses for approximately $1.06 billion.

More... »

National MS Society, GE Healthcare partner

Wednesday, October 2, 2013 01:08 PM

The National Multiple Sclerosis Society is collaborating with GE Healthcare through Fast Forward, a nonprofit subsidiary of the National Multiple Sclerosis Society, to co-fund a clinical study with the GE investigational PET tracer, GE180, in patients with multiple sclerosis (MS). The clinical study, which will be enrolling patients in the U.K., is aimed to aid in physicians' understanding of whether imaging neuroinflammation in MS patients before and after treatment with natalizumab (Tysabri) can help identify which patients may respond to treatment.

More... »

Sanofi appoints two new members to executive committee

Friday, May 3, 2013 12:22 PM

Global healthcare company Sanofi is creating two new units, global commercial operations and global divisions and strategic commercial development, to replace the former global operations unit. Peter Guenter, currently senior vice president, Europe, will be appointed executive vice president of global commercial operations. Pascale Witz, currently president and CEO of medical diagnostics at GE Healthcare, will join Sanofi as executive vice president of global divisions and strategic commercial development. Both Guenter and Witz will join the executive committee.

More... »

Merck, GE Healthcare collaborate on imaging biomarkers for BACE inhibitor program

Wednesday, December 19, 2012 01:18 PM

Merck and GE Healthcare have formed a clinical study collaboration, license and supply agreement for use of [18F]Flutemetamol, an investigational positron emission tomography (PET) imaging agent, to support Merck's development of MK-8931, a novel oral beta amyloid precursor protein site cleaving enzyme (BACE) inhibitor and Merck's lead investigational candidate for Alzheimer's disease (AD).

More... »

AMRI, GE Healthcare extend long term supply relationship

Monday, December 10, 2012 01:16 PM

AMRI, a global contract research and manufacturing organization, has extended its commercial supply relationship with GE Healthcare for Aminobisamide Hydrochloride (ABA).

More... »


CWWeekly

March 30

Icon, Carnegie Mellon partner to research ways to improve study patients' understanding of Informed Consent

Veeva launches OpenKey, partner program to unlock difficult access to, restrictions on customer reference data

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs